{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Fenofibrate+%28drug%29&page=2",
    "query": {
      "intervention": "Fenofibrate (drug)",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 83,
    "total_pages": 9,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Fenofibrate+%28drug%29&page=3&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Fenofibrate+%28drug%29&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-03T20:46:47.020Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02452255",
      "title": "Fenofibrate and Propranolol in Burn Patients",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Burn"
      ],
      "interventions": [
        {
          "name": "Fenofibrate",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Propranolol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "The University of Texas Medical Branch, Galveston",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "Up to 80 Years"
      },
      "enrollment_count": 18,
      "start_date": "2015-11",
      "completion_date": "2019-07-12",
      "has_results": false,
      "last_update_posted_date": "2019-11-29",
      "last_synced_at": "2026-10-03T20:46:47.020Z",
      "location_count": 1,
      "location_summary": "Galveston, Texas",
      "locations": [
        {
          "city": "Galveston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02452255"
    },
    {
      "nct_id": "NCT00891293",
      "title": "A Second Open-Label Extension of a Double-Blind, Parallel, Phase IV Study to Assess the Efficacy and Safety of Adjunctive Lovaza® (Formerly Known as Omacor®) Therapy in Hypertriglyceridemic Subjects Treated With Antara™",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Hypertriglyceridemia"
      ],
      "interventions": [
        {
          "name": "Antara (fenofibrate) + Lovaza (omega-3-acid ethyl esters)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "79 Years",
        "sex": "ALL",
        "summary": "18 Years to 79 Years"
      },
      "enrollment_count": 93,
      "start_date": "2006-03",
      "completion_date": "2008-05",
      "has_results": true,
      "last_update_posted_date": "2011-01-25",
      "last_synced_at": "2026-10-03T20:46:47.020Z",
      "location_count": 32,
      "location_summary": "Spring Valley, California • Washington D.C., District of Columbia • Coral Gables, Florida + 27 more",
      "locations": [
        {
          "city": "Spring Valley",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Coral Gables",
          "state": "Florida"
        },
        {
          "city": "Hollywood",
          "state": "Florida"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00891293"
    },
    {
      "nct_id": "NCT01025492",
      "title": "Study of Trilipix Effects on Lipids and Arteries",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Dyslipidemia"
      ],
      "interventions": [
        {
          "name": "Trilipix",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Utah",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "30 Years to 75 Years"
      },
      "enrollment_count": 24,
      "start_date": "2009-11",
      "completion_date": "2011-03",
      "has_results": true,
      "last_update_posted_date": "2016-09-01",
      "last_synced_at": "2026-10-03T20:46:47.020Z",
      "location_count": 1,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01025492"
    },
    {
      "nct_id": "NCT00357500",
      "title": "Etoposide, Cyclophosphamide, Thalidomide, Celecoxib, and Fenofibrate in Relapsed or Progressive Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Central Nervous System Tumor, Pediatric",
        "Leukemia",
        "Lymphoma",
        "Neuroblastoma",
        "Sarcoma",
        "Unspecified Childhood Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "celecoxib",
          "type": "DRUG"
        },
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "etoposide",
          "type": "DRUG"
        },
        {
          "name": "fenofibrate",
          "type": "DRUG"
        },
        {
          "name": "thalidomide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dana-Farber Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "Up to 21 Years"
      },
      "enrollment_count": 101,
      "start_date": "2005-01",
      "completion_date": "2013-12",
      "has_results": true,
      "last_update_posted_date": "2014-10-01",
      "last_synced_at": "2026-10-03T20:46:47.020Z",
      "location_count": 10,
      "location_summary": "Hartford, Connecticut • Miami, Florida • Chicago, Illinois + 7 more",
      "locations": [
        {
          "city": "Hartford",
          "state": "Connecticut"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Scarborough",
          "state": "Maine"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00357500"
    },
    {
      "nct_id": "NCT00559962",
      "title": "Evaluate Low Doses of AEGR-733 on Hepatic Fat Accumulation by MRS",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hyperlipidemia"
      ],
      "interventions": [
        {
          "name": "AEGR-733",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        },
        {
          "name": "AEGR-733 and atorvastatin",
          "type": "DRUG"
        },
        {
          "name": "AEGR-733 and fenofibrate",
          "type": "DRUG"
        },
        {
          "name": "AEGR-733 and ezetimibe",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Aegerion Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 260,
      "start_date": "2007-10",
      "completion_date": "2008-11",
      "has_results": true,
      "last_update_posted_date": "2018-02-23",
      "last_synced_at": "2026-10-03T20:46:47.020Z",
      "location_count": 15,
      "location_summary": "San Diego, California • Santa Rosa, California • Washington D.C., District of Columbia + 10 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Santa Rosa",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00559962"
    },
    {
      "nct_id": "NCT06905054",
      "title": "Pharmacologic Approaches to Preventing Primary Sclerosing Cholangitis Recurrence After Liver Transplantation",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Primary Sclerosing Cholangitis",
        "Liver Transplant, Complications",
        "PSC",
        "Biliary Strictures"
      ],
      "interventions": [
        {
          "name": "Fenofibrate (drug)",
          "type": "DRUG"
        },
        {
          "name": "Blood draw for the laboratory assessment",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "MRI using a hepatobiliary phase contrast agent (Gd-EOB-DPTA)",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 80,
      "start_date": "2025-04-15",
      "completion_date": "2028-07-01",
      "has_results": false,
      "last_update_posted_date": "2026-07-17",
      "last_synced_at": "2026-10-03T20:46:47.020Z",
      "location_count": 1,
      "location_summary": "Scottsdale, Arizona",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06905054"
    },
    {
      "nct_id": "NCT00819910",
      "title": "Rosiglitazone And Fenofibrate Additive Effects on Lipids (RAFAEL)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Hypertriglyceridemia in Type 4 Hyperlipidemia",
        "Non Diabetic Subjects With Normoglycemia"
      ],
      "interventions": [
        {
          "name": "Rosiglitazone",
          "type": "DRUG"
        },
        {
          "name": "Placebo (Rosiglitazone)",
          "type": "DRUG"
        },
        {
          "name": "Placebo (Fenofibrate)",
          "type": "DRUG"
        },
        {
          "name": "Fenofibrate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ahmad Slim",
      "sponsor_class": "FED",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 41,
      "start_date": "2008-09",
      "completion_date": "2010-05",
      "has_results": true,
      "last_update_posted_date": "2014-04-24",
      "last_synced_at": "2026-10-03T20:46:47.020Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00819910"
    },
    {
      "nct_id": "NCT00794963",
      "title": "Aggressive Treatment of Metabolic Syndrome in Patients Receiving Clozapine for Schizophrenia",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Metabolic Syndrome"
      ],
      "interventions": [
        {
          "name": "Pravastatin, Fenofibrate, Metformin, Orlistat, irbesartan",
          "type": "DRUG"
        },
        {
          "name": "As selected by community physician",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Northwell Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "79 Years",
        "sex": "ALL",
        "summary": "19 Years to 79 Years"
      },
      "enrollment_count": 8,
      "start_date": "2008-11",
      "completion_date": "2010-05",
      "has_results": true,
      "last_update_posted_date": "2015-04-15",
      "last_synced_at": "2026-10-03T20:46:47.020Z",
      "location_count": 1,
      "location_summary": "Glen Oaks, New York",
      "locations": [
        {
          "city": "Glen Oaks",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00794963"
    },
    {
      "nct_id": "NCT05080192",
      "title": "Cardiovascular, Pulmonary, and Integrative Functional Phenotypes in COVID-19 Survivors - Effect of Fenofibrate",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Covid19"
      ],
      "interventions": [
        {
          "name": "Fenofibrate",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Pennsylvania",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2021-08-11",
      "completion_date": "2022-05-10",
      "has_results": true,
      "last_update_posted_date": "2024-06-21",
      "last_synced_at": "2026-10-03T20:46:47.020Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05080192"
    },
    {
      "nct_id": "NCT00872599",
      "title": "The Effect of a Peroxisome Proliferator-activated Receptor (PPAR) Alpha Agonist on Cytochrome P450 (CYP) Monooxygenase Activity in Humans",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Hypertension"
      ],
      "interventions": [
        {
          "name": "fenofibrate",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vanderbilt University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 75,
      "start_date": "2009-09",
      "completion_date": "2012-01",
      "has_results": true,
      "last_update_posted_date": "2013-06-28",
      "last_synced_at": "2026-10-03T20:46:47.020Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00872599"
    }
  ]
}